{"id":"placebo-for-dolutegravir-dtg","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4303416","moleculeType":"Small molecule","molecularWeight":"419.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect (psychological and contextual factors) rather than direct drug action. In this case, it serves as a control comparator for dolutegravir (DTG), an integrase inhibitor used in HIV treatment.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:50.463Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in clinical trials of dolutegravir for HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT07336797","phase":"PHASE2","title":"Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy","status":"RECRUITING","sponsor":"Abdelrahman Mahmoud","startDate":"2025-09-01","conditions":"Metabolic Syndrome, Obesity & Overweight, HIV (Human Immunodeficiency Virus)","enrollment":66},{"nctId":"NCT03547908","phase":"PHASE3","title":"Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-05-30","conditions":"HIV-1/HBV Co-Infection","enrollment":244},{"nctId":"NCT03991013","phase":"PHASE2","title":"Tenofovir-lamivudine-dolutegravir Combination as Second-line ART: a Randomised Controlled Trial","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2019-08-08","conditions":"HIV Infections","enrollment":192},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT02519777","phase":"PHASE4","title":"Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-04-21","conditions":"HIV Infections","enrollment":191},{"nctId":"NCT02607956","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":657},{"nctId":"NCT02607930","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-13","conditions":"HIV-1 Infection","enrollment":631},{"nctId":"NCT03110380","phase":"PHASE3","title":"Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-06-12","conditions":"HIV-1-infection","enrollment":567},{"nctId":"NCT04147715","phase":"PHASE1","title":"Evaluation of Safety, Tolerability, Pharmacokinetics, Drug-Drug and Food Interactions of Single and Multiple Doses of S-648414 in Healthy Adults","status":"COMPLETED","sponsor":"Shionogi","startDate":"2019-10-09","conditions":"Healthy Volunteer","enrollment":98},{"nctId":"NCT03060447","phase":"PHASE1","title":"Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-05-09","conditions":"HIV-1 Infection","enrollment":25},{"nctId":"NCT02603120","phase":"PHASE3","title":"Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT02397694","phase":"PHASE2","title":"Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-03-23","conditions":"HIV-1 Infection","enrollment":98},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02858401","phase":"PHASE1","title":"Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-01-29","conditions":"HIV-1 Infection","enrollment":48},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01568892","phase":"PHASE3","title":"Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2012-04-18","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02500446","phase":"PHASE4","title":"Dolutegravir Impact on Residual Replication","status":"COMPLETED","sponsor":"University of Melbourne","startDate":"2015-09-28","conditions":"HIV","enrollment":40},{"nctId":"NCT00708110","phase":"PHASE2","title":"Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2008-06","conditions":"Infection, Human Immunodeficiency Virus","enrollment":35},{"nctId":"NCT01214993","phase":"PHASE1","title":"A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2010-10","conditions":"Infections, Human Immunodeficiency Virus and Tuberculosis","enrollment":38},{"nctId":"NCT01498861","phase":"PHASE1","title":"Drug Interaction Study Between Dolutegravir and an Oral Contraceptive Containing Norgestimate and Ethinylestradiol","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-12","conditions":"Infection, Human Immunodeficiency Virus","enrollment":16},{"nctId":"NCT00942136","phase":"PHASE1","title":"GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Healthy Volunteer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo for dolutegravir (DTG)","genericName":"Placebo for dolutegravir (DTG)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in clinical trials of dolutegravir for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}